TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..)~* 18 years of age and older~* Liver biopsy (percutaneous or transjugular or surgical) performed within 6 months, as part of routine clinical care.~* Liver transplant or liver resection performed within 6 months, as part of routine clinical care.~* Patient is able to give informed consent for this study and agrees to provide a blood sample~Control group~* Patients without history of liver disease and healthy volunteers~* 18 years of age and older~* Subject is able to give informed consent for this study and agrees to provide a blood sample~Exclusion Criteria:~* Age less than 18 years~* Unable or unwilling to give informed consent~* Contra-indications to MRI~* Electrical implants such as cardiac pacemakers or perfusion pumps~* Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants~* Ferromagnetic objects such as jewelry or metal clips in clothing~* Pregnant subjects~* Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Perfusion MRI (Type: EXPERIMENTAL): chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medication Adherence Clinical Decision Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One or more of the following clinical criteria:~A. In the 12 months prior to the index visit, most recent hemoglobin A1C ≥8% AND have one or more active non-insulin glycemic medications on their electronic health record (EHR) medication list AND a potential adherence issue for one or more of these medications based on the Epic Medication Adherence score (e-PDC \<80%, moderate or high confidence).~B. Two consecutive encounters with BP values ≥140/90 mm Hg AND one or more BP medications on their EHR medication list AND a potential adherence issue identified (e-PDC \<80%, moderate/high confidence).~C. Meet the American College of Cardiology/American Heart Association (ACC/AHA) criteria listed below for moderate or high-intensity statin use AND a statin medication on their EHR medication list AND a potential statin adherence issue identified (e-PDC \<80%, moderate/high confidence):~1. Age \>21 with atherosclerotic cardiovascular disease (ASCVD) identified by a cardiovascular disease (CVD) diagnosis on the problem list or two or more International Classification of Diseases (ICD)-10 diagnostic codes in the last 2 years~2. Age \>21 and LDL \>190 mg/dL~3. Aged 40 to 75 AND diabetes identified by the diagnosis on the problem list or two or more ICD-10 diagnostic codes in the last 2 years~4. Aged 40 to 75 with 10-year CV Risk Score \>7.5% based on the ACC/AHA 10-year ASCVD risk equation.~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from the study analysis:~1. Patients enrolled in hospice,~2. Patients with active cancer or undergoing chemotherapy~3. Patients with pregnancy in the last year~4. Patients without HealthPartners insurance coverage for at least 11 of the 12 months before the index visit will be excluded from cost analysis.~5. For Statin cohort, ≥1 LDL result \<100 mg/dl within 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Patients in the usual care arm receive the basic cardiovascular related clinical decision support which is considered standard of care at the organization.
- Adherence Intervention (Type: EXPERIMENTAL): Patients in the medication adherence enhanced clinical decision support received the enhanced decision support intervention over a 6 month period. Patients were accrued over 6 months and followed for 12 months at which point they were assessed for improved medication adherence and clinical outcomes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.~Exclusion Criteria:~* pregnancy,~* proven Candida infection,~* prophylactic or curative antifungal treatment within the last 2 months,~* contraindication to oral drug administration,~* known allergy to nystatin or its derivatives, and prior inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nystatin (Type: ACTIVE_COMPARATOR): surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
- Control (Type: PLACEBO_COMPARATOR): surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients 18-50 years of age, who have signed an informed consent form.~2. Clinical evidence of asthma~3. Steroid naïve asthmatic patients~4. FEV1 at Screening Visit is \>70 % of the predicted value and at least 2.0 L.~5. Body Mass Index between 18 and 35.~6. Sensitivity to AMP at Screening Visit.~7. FENO levels \>25 ppb at the Screening Visit~Exclusion Criteria:~1. Having received an investigational product within 2 months of Screening Visit.~2. Inability to comply with study procedures or with study treatment intake.~3. Any significant lung disease which is considered by the investigator to be clinically significant.~4. Patients who suffer from Chronic Obstructive Pulmonary Disease (COPD)~5. Previous or current smokers who have a smoking history greater than 5 pack years.~6. Patients with any uncontrolled disease that might, in the judgment of the investigator, place the patients at undue risk or potentially compromise the results or interpretation of the study.~7. Patients with QTc \>450msec at the Screening Visit.~8. Patients with serum potassium \<3.5 mEq/L or \>6 mEq/L.~9. Intolerance/hypersensitivity or any contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids.~10. Patients who have a history of alcohol or substance abuse that in the opinion of the Investigator may be of clinical significance.~11. Patients who have undergone major surgery in the previous 3 months.~12. Patients who have had an exacerbation of asthma, requiring treatment with oral steroids during the last month prior to Screening Visit.~13. Patients treated with slow-release corticosteroids 2 months prior to Screening Visit.~14. Patients currently treated with anti-IgE Antibodies.~15. Patients who have had a respiratory tract infection within 4-weeks prior to Screening Visit.~16. Females not willing to use effective contraceptive measures such as oral contraceptive or intra-uterine device (IUD).~17. Females who are pregnant, lactating or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pMDI
- Low dose (Type: EXPERIMENTAL): BDP/formoterol pMDI low dose
- High dose (Type: EXPERIMENTAL): BDP/Formoterol pMDI high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 2 diabetes who have never received any hypoglycemic treatment；~2. Fasting plasma glucose (FPG) between 7.0 mmol/l (126 mg/dl) and 16.7 mmol/l (300 mg/dl);~3. glycosylated hemoglobin A1C≥8.5%;~4. Aged between 20 and 70 years 5） body mass index (BMI) 22-35 kg/m2.~Exclusion Criteria:~1. Type 1 diabetes or special type of diabetes;~2. Acute complications of diabetes (including DKA, HHS and lactic acidosis)~3. Serious microvascular complications: proliferative stage of retinopathy; urine AER \>300 mg/g or urine protein positive, quantification \>0.5 g/d; uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy;~4. Severe macrovascular complications: acute cerebrovascular accident, acute coronary syndrome, vascular intervention for peripheral arterial disease or amputation requiring hospitalization within 12 months prior to enrollment;~5. Persistently increased blood pressure \>180/110 mmHg;~6. Blood creatinine clearance less than 50 ml/min, alanine aminotransferase ≥2.5×upper limit of normal, total bilirubin ≥1.5×upper limit of normal;~7. Hemoglobin \<100 g/L or need regular blood transfusion;~8. Use of drugs that may influence blood glucose within 12 weeks;~9. Systemic infection or serious concomitant disease; patients with malignancy or chronic diarrhea;~10. Uncontrolled endocrine gland dysfunction;~11. Patients with mental or communication disorders;~12. Chronic cardiac insufficiency, heart function class III and above;~13. Pregnant women, lactating women and women of child bearing age who are not willing to take contraception during the study;~14. Subjects who don't cooperate, cannot be followed up or have difficulty in completing the study considered by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin plus metformin (Type: ACTIVE_COMPARATOR): CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
- Linagliptin (Type: ACTIVE_COMPARATOR): CSII followed by Linagliptin 5mg Qd for 48 weeks
- Metformin (Type: ACTIVE_COMPARATOR): CSII followed by Metformin 0.5 bid for 48 weeks
- Lifestyle alone (Type: ACTIVE_COMPARATOR): No OHA is given after CSII

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Steroid Injection vs Placebo in Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary idiopathic CTS~* Symptoms of classic or probable CTS according to the Katz diagnostic criteria (numbness and/or tingling in at least 2 of the 4 median nerve innervated fingers)~* Failed treatment with wrist splinting (2 months)~* Nerve conduction tests showing median neuropathy at the wrist or, if normal, two orthopedic surgeons independently make CTS diagnosis~* Symptom severity that warranted referral for consideration for surgery~Exclusion Criteria:~* Previous steroid injection for CTS~* Thenar muscle atrophy~* Sensory deficit (two-point discrimination \>8 mm)~* Diabetes, thyroid disorder, or inflammatory disease~* Polyneuropathy or vibration-induced neuropathy~* Current pregnancy~* Previous carpal tunnel surgery on the study hand~* Surgery on the contralateral hand in the past 2 months~* Inability to respond to questionnaires~* Severe medical illness~* Known drug/alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone 80 mg (Type: EXPERIMENTAL): Local injection of 80 mg Methylprednisolone into the carpal tunnel
- Methylprednisolone 40 mg (Type: EXPERIMENTAL): Local injection of 40 mg Methylprednisolone into the carpal tunnel
- Placebo (Type: PLACEBO_COMPARATOR): Local injection of saline into the carpal tunnel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naturally or surgically postmenopausal~* Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse)~Exclusion Criteria:~* Known sensitivity or contraindication to estrogens or progestins~* History or current diagnosis of endometrial hyperplasia~* Recent history of vaginal bleeding of unknown cause~* Recent history or diagnosis of endometriosis~* Any contraindication to estrogen therapy

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmation of a diagnosis of an inborn error of bile acid synthesis/conjugation based upon urine analysis by FAB-MS.~2. Any age~3. Participant must be willing and able to comply with study assessments and procedures.~4. The participant and/or parent/legal guardian must have signed the written informed consent document prior to study start.~Exclusion Criteria~1. No confirmed diagnosis of inborn error of bile acid synthesis/conjugation based upon urine analysis by FAB-MS.

- Gender: ALL
- Minimum Age: 1 Week
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- GlycoCholic Acid, Study Drug (Type: EXPERIMENTAL): An open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female, of any race, at least 18 years of age (inclusive).~* Freely provides both verbal and written informed consent.~* Has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation.~* Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.~* Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4 (the face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded from this calculation, if psoriasis is present).~Key Exclusion Criteria:~* Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the Investigator.~* Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the Investigator.~* Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the Investigator.~* Is pregnant, nursing an infant, or planning a pregnancy during the study period.~* Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently participating in another clinical study with an investigational drug or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-122 Lotion (Type: EXPERIMENTAL): Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks.
- IDP-122 Vehicle Lotion (Type: ACTIVE_COMPARATOR): Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beige Fat, Energy, and the Natriuretic Peptide System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 18-55 years~* Body Mass Index (BMI) \>= 18.5 and \<25 kg/m2 (lean), or BMI 30 kg/m2 (obese)~Exclusion Criteria:~* Significant pulmonary, liver, or renal disease~* Heart failure (any type) or unstable coronary artery disease~* Diabetes Mellitus (Types 1 and 2)~* Thyroid dysfunction~* Active malignancy~* Chronic inflammatory diseases, such as inflammatory bowel disease, hepatitis, rheumatoid arthritis~* Current use of medications likely to affect energy homeostasis, including glucocorticoids, amphetamines, and beta blockers~* Currently pregnant or breastfeeding, or unwilling to avoid becoming pregnant or breastfeeding during study duration~* Significant claustrophobia that would prevent the use of the metabolic cart as part of the study protocol~* Hemoglobin A1c (HbA1c) \>= 6.5%~* Liver Function Tests (LFTs) elevated \>3x upper limit of normal~* Estimated Glomerular Filtration Rate (eGFR) \<40 ml/min~* Currently abnormal thyroid stimulating hormone (TSH)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- obese and lean individuals (Type: None): obese and lean individuals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You are between the ages of 18 and 45~* You have had a history for at least a year of COPD symptoms~* Your current asthma treatment is limited to short-acting beta-agonists(such as albuterol)~* You have a history of smoking one pack of cigarettes per day for 7 years~* You will not be away from home for more than 5 days during the study~Exclusion Criteria:~* You are unwilling to limit your alcohol use to less than 5 drinks per week~* You have been in a research study with an investigational drug or vaccine in the last 4 weeks~* You have donated blood in the last 4 weeks~* You have been hospitalized or had major surgery in the last 4 weeks~* You have been treated in the emergency room within the last 4 weeks or hospitalized within the last 3 months for your asthma~* You have a history of heart problems in the last 6 months~* You have a history of stomach problems~* You are unwilling to avoid grapefruit juice throughout the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all of the following criteria to be eligible for inclusion in the study:~1. Patients with confirmed diagnosis of Ulcerative Colitis or Crohn's Disease.~2. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.~3. Patient eligible to receive INFLECTRA for the treatment of their disease per approved drug label (patients with fistula, or stoma are eligible).~Exclusion Criteria:~-Patients meeting any of the following criteria will not be included in the study:~1. Patient previously failed treatment with REMICADE or INFLECTRA/CT P13.~2. Any reported contraindications for INFLECTRA/CT P13 or REMICADE.~3. Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis (Type: None): Group treated with Inflectra for Ulcerative Colitis
- Crohn's Disease (Type: None): Group treated with Inflectra for Crohn's Disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete